Corvia Medical raises $55m to complete confirmatory heart shunt trial
The US-based company's trial began in 2022 and is currently underway at more than 65 institutions across three continents with 750 patients enrolled, according to the trial's listing on Clinicaltrials.gov.
Increasing Corvia's current funding to around $150m, the latest set of funds originated from the company's existing investment syndicate of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, along with two strategic investors.
Corvia anticipates the double-blind, randomised, sham-controlled confirmatory RESPONDER-HF (NCT05425459) trial of the Corvia atrial shunt system, which is being evaluated to treat heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF), to generate the final clinical data required to support a regulatory filing with the US Food and Drug Administration (FDA).
The atrial shunt works by creating a small passage between the heart's left and right atria, enabling blood to flow from the high-pressure left side to the lower-pressure right side.
Trial patients randomised to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transoesophageal echocardiography (TEE) guided trans-septal puncture and with the Corvia atrial shunt implant procedure. In addition, patients randomised to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
Upon completion, patients will be evaluated at pre-specified time intervals and followed for five years.
Corvia CEO George Fazio said: "We are profoundly grateful for the unwavering support of our longstanding investors as we advance toward FDA submission of the Corvia atrial shunt.
"Their commitment furthers our mission to bring this transformative heart failure treatment to millions of patients worldwide."
The funding will provide Corvia with the resources needed to navigate the approval process for the Corvia shunt system and introduce the therapy to the market, added Corvia board chair Paul LaViolette.
Research indicates that around 65 million people worldwide have heart failure, with a majority affected by HFpEF.
In October 2023, Corvia announced positive safety and efficacy results from its REDUCE LAP-HF II (NCT03088033) randomised Phase III trial of its atrial shunt. In comparison to the sham control, patients showed a 50% reduction in the rate of heart failure events and a sustained improvement in quality of life as measured on the Kansas City Cardiomyopathy Questionnaire (KCCQ).
"Corvia Medical raises $55m to complete confirmatory heart shunt trial" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
7 minutes ago
- Business Journals
Kohl's adds tech leaders to C-suite
They are the first leadership team hires announced since Michael Bender took over as interim CEO following the April 30 firing of Ashley Buchanan. The new members of the company's digital team join as the Menomonee Falls-based retailer continues to refine its digital strategy.
Business Journals
7 minutes ago
- Business Journals
FM names new technology executive
The Johnston-based Factory Mutual Insurance Co. has named a new chief information officer and SVP. Tara Long will lead the global commercial property insurer's technology strategy, FM said Tuesday. She'll ensure the company has the right architecture, skills and tools to support clients, business operations and long-term growth. Long arrives from MassMutual, where she served as chief technology officer and head of enterprise infrastructure services. She previously held roles at Gerber Scientific and PricewaterhouseCoopers. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events 'Tara brings a wealth of experience in leading digital transformations and driving large-scale operational improvements to enhance the client experience and advance business objectives,' said Randy Hodge, FM's COO. 'She will collaborate closely with partners from across FM to ensure our technology initiatives not only serve our clients effectively but also position them — and our business — for long-term success.' Long holds an MBA with a concentration in management information systems from Western New England University and a bachelor's in psychology from Mount Holyoke College. She succeeds Srini Krishnamurthy, who is now leading FM India. FM recently expanded its footprint in Bengaluru at the center of India's high-tech industry, and also plans to open a new sales office in Mumbai. It also recently signed a lease in Boston at a yet-to-be-completed office tower. FM is a mutual insurance group dedicated to property risk management. It touts its expertise in scientific research, engineering and technology underwriting, and maintains a focus on commercial property insurance. Its owners represent many of the world's largest organizations, including one of every four Fortune 500 companies, the company says.
San Francisco Chronicle
7 minutes ago
- San Francisco Chronicle
FDA warns about possibly radioactive shrimp sold at Walmart
The Food and Drug Administration is warning consumers not to eat certain frozen shrimp sold at Walmart after tests raised concerns about possible radioactive contamination. The agency said the shrimp, marketed under Walmart's Great Value brand, was imported from Indonesian seafood processor PT. Bahari Makmur Sejati, also known as BMS Foods. While no contaminated shrimp has entered the U.S. food supply, the FDA said Tuesday that shipments linked to the company violated federal food safety laws and may pose a health risk. U.S. Customs and Border Protection first detected Cesium-137, a radioactive isotope, in shipping containers at ports in Los Angeles, Houston, Savannah, Ga. and Miami. FDA testing later confirmed the presence of the isotope in one sample of breaded shrimp from the same supplier. That shipment was denied entry into the country. Although the levels of Cesium-137 detected were well below federal thresholds, regulators said long-term exposure to even low doses could increase the risk of cancer. 'Avoiding products like the shipment FDA tested with similar levels of Cs-137 is a measure intended to reduce exposure to low-level radiation that could have health impacts with continued exposure over a long period of time,' the agency said in its notice. The products under recall include: Great Value frozen raw shrimp, lot code 8005540-1, best by March 15, 2027 Great Value frozen raw shrimp, lot code 8005538-1, best by March 15, 2027 Great Value frozen raw shrimp, lot code 8005539-1, best by March 15, 2027 Consumers are urged to throw away the shrimp if purchased. Distributors and retailers are instructed not to sell or serve it. The FDA has placed PT. Bahari Makmur Sejati on an import alert, effectively banning its shrimp from entering the U.S. until safety concerns are resolved. The investigation is ongoing.
